Flarend R E, Hem S L, White J L, Elmore D, Suckow M A, Rudy A C, Dandashli E A
Department of Physics, Purdue University, West Lafayette, IN 47907, USA.
Vaccine. 1997 Aug-Sep;15(12-13):1314-8. doi: 10.1016/s0264-410x(97)00041-8.
Aluminium hydroxide (AH) and aluminium phosphate (AP) adjuvants, labelled with 26Al, were injected intramuscularly (i.m.) in New Zealand White rabbits. Blood and urine samples were collected for 28 days and analysed for 26Al using accelerator mass spectrometry to determine the absorption and elimination of AH and AP adjuvants. 26Al was present in the first blood sample (1 h) for both adjuvants. The area under the blood level curve for 28 days indicates that three times more aluminium was absorbed from AP adjuvant than AH adjuvant. The distribution profile of aluminium to tissues was the same for both adjuvants (kidney > spleen > liver > heart > lymph node > brain). This study has demonstrated that in vivo mechanisms are available to eliminate aluminium-containing adjuvants after i.m. administration. In addition, the pharmacokinetic profiles of AH and AP adjuvants are different.
用26Al标记的氢氧化铝（AH）和磷酸铝（AP）佐剂通过肌肉注射（i.m.）的方式注入新西兰白兔体内。采集血液和尿液样本，为期28天，并使用加速器质谱法分析其中的26Al，以确定AH和AP佐剂的吸收和消除情况。两种佐剂的首个血液样本（1小时）中均检测到了26Al。28天的血药浓度曲线下面积表明，AP佐剂吸收的铝是AH佐剂的三倍。两种佐剂的铝在组织中的分布情况相同（肾脏>脾脏>肝脏>心脏>淋巴结>大脑）。本研究表明，肌肉注射含铝佐剂后，体内存在消除这些佐剂的机制。此外，AH和AP佐剂的药代动力学特征不同。
